Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO rejects GSK...

    CDSCO rejects GSK request to skip Phase III trial for Influenza Vaccine for higher age groups

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-05-22T17:25:50+05:30  |  Updated On 17 Aug 2021 1:04 PM IST

    New Delhi: One of the oldest pharmaceutical and healthcare companies in India, GlaxoSmithKline recently presented before the Subject Expert Committee functional under the Central Drugs Standard Control Organization (CDSCO) for a waiver of clinical trial of Inactivated Influenza Vaccine (Split Virion). However, CDSCO did not grant permission to skip the clinical trial and directed them to conduct the Phase III trial.


    The recommendation came after the firm presented the proposal for waiver of the clinical trial requirement for an extension of the indication to higher age groups.


    Much to its dismay, the committee did not rule in favour of the proposal presented by GSK. Instead, the SEC committee recommended that "the firm should conduct Phase III local clinical trial in the proposed age group."


    An inactivated vaccine (or killed vaccine) is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed, thereby implying extra caution needs to be exercised as compared to a drug (formulation) trial.


    According to the WHO guidelines for clinical evaluation of vaccines, the phase III studies that are large-scale clinical trials designed to provide data on vaccine efficacy and safety are necessary.


    These studies are usually performed in large populations to evaluate the efficacy and safety of formulation(s) of the immunologically active component(s).


    A couple of years ago, CDSCO had shown a green flag to Zydus Cadila's tetravalent inactivated influenza vaccine for seasonal flu. Medical Dialogues had earlier reported that Zydus had received approvals from the Drug Controller General of India (DCGI), CDSCO and Central Drug Laboratory (CDL) to market the tetravalent inactivated influenza vaccine Vaxiflu 4 for seasonal flu. For instance, Influenza is a major respiratory pathogen causing annual outbreaks and occasional pandemics.


    Also Read: Zydus Cadila to launch seasonal flu vaccine in India


    Presently, GSK's proposal for a waiver of the phase III trial regarding the Inactivated Influenza Vaccine has not been considered and the firm has been recommended to conduct the same.


    GSK is an Indian subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.


    Its product portfolio includes prescription medicines and vaccines. It's prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.


    The company also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others.

    anti infectivescancerCardiovascular diseaseCDSCOCentral Drugs Standard Control Organizationcervical cancerchickenpoxDermatologydiabetesdiphtheriaDrug Controller General of IndiaFlu vaccineGlaxoSmithKlineGSKgynaecologyhepatitis Ahepatitis BInactivated vaccinesinfluenzainvasive diseaseMedical DevicesoncologypandemicspertussisPhase IIIphase III trialrespiratory diseasesrespiratory pathogenrotavirusSEC CommitteeSplit ViriontetanusvaccinevaccinesVirionzydusZydus Cadila

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok